public:: true

# drug discovery
```json-ld
{
  "@context": "https://narrativegoldmine.com/context/v1.jsonld",
  "@id": "urn:visionflow:page:03ea62f430893a5f9234b5662908d7509085c303667af13417b74e7dc16f2fa8",
  "@type": "Page",
  "vc:slug": "drug-discovery",
  "title": "drug discovery",
  "vc:public": true,
  "vc:outboundWikilinks": [],
  "vc:schemaVersion": 2,
  "prov:wasAttributedTo": {
    "@id": "did:nostr:jjohare"
  },
  "prov:generatedAtTime": {
    "@value": "2026-05-19T21:00:00Z",
    "@type": "xsd:dateTime"
  }
}
```

```json-ld
{
  "@context": "https://narrativegoldmine.com/ns/v2.jsonld",
  "@id": "urn:ngm:class:drug-discovery",
  "@type": "Class",
  "label": "Drug Discovery",
  "definition": "Drug discovery is the multidisciplinary scientific process of identifying and validating novel therapeutic compounds that modulate disease-relevant biological targets, spanning target identification, hit discovery, lead optimisation, and preclinical candidate nomination. The modern discipline applies machine learning, deep learning, graph neural networks, and generative modelling to predict molecular properties such as binding affinity, selectivity, and ADMET profiles — dramatically accelerating virtual screening and de novo molecular design. Structural biology tools including protein structure prediction (e.g. AlphaFold) underpin structure-based drug design by supplying accurate 3D target models at proteome scale. The field sits at the intersection of cheminformatics, structural biology, computational chemistry, and clinical informatics, with AI methods increasingly embedded throughout the entire development pipeline from target discovery through biomarker identification and patient stratification.",
  "domain": "artificial-intelligence",
  "maturity": "emerging",
  "subClassOf": [
    {
      "@id": "urn:ngm:class:ai-application",
      "label": "AI Application"
    }
  ],
  "relations": {
    "uses": [
      {
        "@id": "urn:ngm:class:graph-neural-network",
        "label": "Graph Neural Network"
      },
      {
        "@id": "urn:ngm:class:generative-model",
        "label": "Generative Model"
      },
      {
        "@id": "urn:ngm:class:transformer",
        "label": "Transformer"
      },
      {
        "@id": "urn:ngm:class:reinforcement-learning",
        "label": "Reinforcement Learning"
      },
      {
        "@id": "urn:ngm:class:variational-autoencoder",
        "label": "Variational Autoencoder"
      }
    ],
    "enables": [
      {
        "@id": "urn:ngm:class:clinical-trials",
        "label": "Clinical Trials"
      },
      {
        "@id": "urn:ngm:class:precision-medicine",
        "label": "Personalised Medicine"
      },
      {
        "@id": "urn:ngm:class:biomarker-discovery",
        "label": "Biomarker Discovery"
      }
    ],
    "dependsOn": [
      {
        "@id": "urn:ngm:class:active-learning",
        "label": "Active Learning"
      },
      {
        "@id": "urn:ngm:class:protein-structure-prediction",
        "label": "Protein Structure Prediction"
      }
    ],
    "relatedTo": [
      {
        "@id": "urn:ngm:class:simulation",
        "label": "Simulation"
      },
      {
        "@id": "urn:ngm:class:genomics",
        "label": "Genomics"
      },
      {
        "@id": "urn:ngm:class:digital-twin",
        "label": "Digital Twin"
      }
    ],
    "bridgesTo": [
      {
        "@id": "urn:ngm:class:regulatory-compliance",
        "label": "Regulatory Compliance"
      },
      {
        "@id": "urn:ngm:class:federated-learning",
        "label": "Federated Learning"
      }
    ]
  },
  "sameAs": [
    {
      "@id": "urn:ngm:class:ai-drug-discovery",
      "label": "AI Drug Discovery"
    },
    {
      "@id": "urn:ngm:class:computer-aided-drug-design",
      "label": "Computer-Aided Drug Design"
    }
  ],
  "quality": 0.72,
  "provenance": {
    "attributedTo": "did:nostr:ontology-mesh",
    "generatedAt": "2026-06-13T00:00:00Z",
    "inferenceRule": "ManualEnrichment"
  }
}
```

- ### Definition
  - Drug discovery is the multidisciplinary scientific process of identifying, designing, and validating novel therapeutic compounds that modulate disease-relevant biological targets. It encompasses [[Target Identification]], [[Virtual Screening]], [[Lead Optimisation]], and preclinical candidate nomination, with modern methods applying [[Machine Learning]], [[Graph Neural Network]], and [[Generative Model]] approaches to predict molecular properties — including binding affinity, selectivity, and ADMET profiles (absorption, distribution, metabolism, excretion, toxicity). Structural biology tools such as [[Protein Structure Prediction]] (exemplified by AlphaFold) supply accurate 3D target models at proteome scale, underpinning structure-based design. The field sits at the convergence of [[Cheminformatics]], [[Structural Biology]], computational chemistry, and [[Biomedical Data]] science, with AI increasingly embedded throughout the entire development pipeline.

- ### Overview
  - Drug discovery addresses one of the most resource-intensive challenges in applied science: identifying safe, efficacious small molecules or biologics that can become approved medicines.
  - The traditional pipeline spans target identification → hit discovery → lead optimisation → preclinical development → [[Clinical Trials]] → regulatory submission, a timeline that historically averaged ten to fifteen years with attrition rates exceeding 90%.
  - Computational and AI-driven approaches compress this pipeline by:
    - Replacing costly physical high-throughput screens with [[Virtual Screening]] of billions of compounds using deep learning affinity predictors.
    - Generating novel molecular scaffolds via generative chemistry rather than relying solely on synthesised compound libraries.
    - Predicting toxicity and pharmacokinetic properties early, reducing late-stage failures.
    - Integrating multimodal biological data ([[Genomics]], [[Proteomics]], clinical records) for richer target validation and patient stratification.
  - Major pharmaceutical companies and AI-native biotechs (e.g. Exscientia, Recursion, Insilico Medicine) have demonstrated that AI-designed compounds can enter clinical trials, validating the paradigm in practice.

- ### Key Components
  - **Target Identification and Validation**
    - Uses [[Genomics]], [[Proteomics]], and [[Multi-Omics]] data to identify disease-modifying biological targets (proteins, nucleic acids, pathways).
    - [[Knowledge Graph]] and network medicine approaches map disease-gene-protein relationships to prioritise targets.
    - [[Causal Inference]] methods help distinguish drivers from passengers in disease biology.
  - **Virtual Screening**
    - Structure-based screening docks candidate ligands into target binding sites predicted by [[Protein Structure Prediction]] tools such as AlphaFold.
    - Ligand-based screening trains [[Machine Learning]] models on known active/inactive compound profiles to score large libraries.
    - [[Graph Neural Network]] models operating on molecular graphs outperform fingerprint-based methods on many benchmark datasets.
  - **Generative Molecular Design**
    - [[Variational Autoencoder]] and normalising flow models learn latent molecular representations and decode novel structures.
    - [[Transformer]] architectures trained on SMILES strings (e.g. ChemBERTa, MolGPT) generate and evaluate candidate molecules.
    - [[Reinforcement Learning]] with multi-objective reward functions guides de novo molecule optimisation towards desired potency, selectivity, and pharmacokinetic properties simultaneously.
    - Diffusion models increasingly generate 3D molecular conformations directly, bypassing SMILES linearisation.
  - **ADMET Prediction**
    - Machine learning models trained on experimental ADMET datasets predict absorption, distribution, metabolism, excretion, and toxicity properties from molecular structure alone, enabling early triage before synthesis.
    - [[Active Learning]] frameworks iteratively select the most informative compounds for wet-lab assay, maximising information gain per experiment.
  - **Biomarker Discovery and Patient Stratification**
    - [[Multi-Omics]] integration and [[Federated Learning]] across hospital datasets identify predictive biomarkers for patient selection in [[Clinical Trials]].
    - [[Digital Twin]] patient models simulate individual drug responses to support [[Personalised Medicine]].
  - **Molecular Dynamics and Free Energy Perturbation**
    - [[Molecular Dynamics Simulation]] and enhanced sampling methods quantify binding free energies with greater physical rigour than docking alone.
    - AI force fields (e.g. ANI, MACE) accelerate quantum-mechanical-quality simulations by orders of magnitude.

- ### Applications and Use Cases
  - **Oncology** — identification of kinase inhibitors and degrader (PROTAC) scaffolds targeting oncoproteins; AI biomarker discovery for patient stratification in immuno-oncology trials.
  - **Infectious Disease** — rapid screening against viral proteases and polymerases; AlphaFold-enabled structure-based design against novel pathogen targets with limited prior structural data.
  - **Rare and Neglected Diseases** — generative models enable economic screening of large virtual libraries for targets where traditional HTS would be cost-prohibitive.
  - **CNS Drug Discovery** — blood-brain barrier permeability prediction and CNS-ADMET models guide the challenging design of neuroactive agents.
  - **Antibody and Biologic Design** — sequence-to-structure models (e.g. ESMFold, RFdiffusion) and [[Generative Model]] approaches design novel protein therapeutics and antibodies.
  - **Repurposing and Combination Therapy** — [[Knowledge Graph]] link-prediction identifies approved drugs with predicted activity against new targets, reducing timeline to clinical proof-of-concept.

- ### Relationships
  - uses:: [[Graph Neural Network]]
  - uses:: [[Generative Model]]
  - uses:: [[Transformer]]
  - uses:: [[Reinforcement Learning]]
  - uses:: [[Variational Autoencoder]]
  - uses:: [[Molecular Dynamics Simulation]]
  - requires:: [[Cheminformatics]]
  - requires:: [[Structural Biology]]
  - requires:: [[Biomedical Data]]
  - enables:: [[Clinical Trials]]
  - enables:: [[Personalised Medicine]]
  - enables:: [[Biomarker Discovery]]
  - dependsOn:: [[Active Learning]]
  - dependsOn:: [[Protein Structure Prediction]]
  - dependsOn:: [[High-Throughput Screening]]
  - relatedTo:: [[Simulation]]
  - relatedTo:: [[Genomics]]
  - relatedTo:: [[Proteomics]]
  - relatedTo:: [[Multi-Omics]]
  - relatedTo:: [[Digital Twin]]
  - bridges-to:: [[Regulatory Compliance]]
  - bridges-to:: [[Federated Learning]]
  - contrastsWith:: [[Traditional High-Throughput Screening]]

- ### Standards and Context
  - **Regulatory Frameworks**
    - Regulatory agencies (FDA, EMA, MHRA) have published guidance on the use of AI/ML in drug development (e.g. FDA's action plan for AI/ML-based software as a medical device).
    - ICH S7A/S7B guidelines govern safety pharmacology data still required even when AI prediction informs lead selection.
    - FDA's Complex Innovative Trial Designs programme facilitates adaptive [[Clinical Trials]] informed by biomarker data and computational models.
  - **Data Standards**
    - SMILES (Simplified Molecular Input Line Entry System) and InChI are canonical molecular representation standards used as model inputs.
    - ChEMBL, PubChem, and the Protein Data Bank (PDB) are primary open data resources underpinning training datasets.
    - FAIR data principles (Findable, Accessible, Interoperable, Reusable) are increasingly mandated for AI training data in regulated pharmaceutical contexts.
  - **Benchmarks**
    - MoleculeNet, TDC (Therapeutics Data Commons), and CASP (Critical Assessment of Protein Structure Prediction) benchmark model performance on standardised splits.
    - ADMET Evaluation Benchmark (ADE Bench) provides standardised toxicity and pharmacokinetics evaluation.
  - **Organisations and Consortia**
    - MELLODDY consortium (federated multi-pharma ML), Open Targets, Pistoia Alliance, and the Structural Genomics Consortium promote open data and pre-competitive collaboration.
    - ELIXIR and the European Open Science Cloud support FAIR biomedical data infrastructure for the field.

- ### Limitations and Open Challenges
  - **Distribution shift** — models trained on synthesisable, drug-like chemical space may fail when exploring structurally novel regions.
  - **Data scarcity** — experimental ADMET datasets are small and imbalanced; active learning and transfer learning partially address this.
  - **Explainability** — black-box deep learning models are difficult to interpret; regulatory bodies increasingly expect mechanistic rationale supporting AI-generated predictions.
  - **Synthesis accessibility** — generative models can propose molecules that are chemically attractive but synthetically intractable; synthetic accessibility scoring and retrosynthesis planning tools ([[Retrosynthesis]], [[Reaction Prediction]]) are integrated into pipelines to address this.
  - **Clinical translation gap** — even optimal preclinical AI predictions cannot substitute for empirical human safety and efficacy data required by regulators.
  - **Reproducibility** — heterogeneous experimental conditions and data provenance issues in public datasets complicate fair benchmarking.

- ### Provenance
  - sources:: ChEMBL database; Therapeutics Data Commons; AlphaFold Protein Structure Database; FDA AI/ML Action Plan; Open Targets platform
  - updated:: 2026-06-13
  - migration-date:: 2026-05-19T00:00:00Z
